TMTiza Wuri Mawaddah

Tiza Wuri Mawaddah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tiza Wuri Mawaddah has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhancing immunogenicity: Evaluating the polio antigen immune response in hexavalent vaccine formulations

    by Tiza Wuri Mawaddah, Elisa D. Pratiwi, Arif Rahman Sadjuri, Dimas Tri Nugroho, Arip Hidayat, Acep R. Wijayadikusumah, Astria N. Nidom, Zakiyyan I. Ayyuba, Kadek Rachmawati, Suwarno Suwarno, et al.

    Hexavalent vaccines simplify childhood immunization by combining antigens against six diseases in a single formulation; however, the immunogenicity of each component must be evaluated. This study assessed poliovirus-specific immunoglobulin G (IgG) responses elicited by candidate hexavalent vaccines containing different doses of Sabin strain-derived inactivated poliovirus vaccine (sIPV). A preclinical study was conducted using 40 Wistar rats allocated to five groups: hexavalent vaccine containing low-, medium-, or high-dose sIPV; pentavalent vaccine combined with sIPV; or adjuvant control. Each group comprised four male and four female rats. The animals received primary immunization at week 0 and booster doses at weeks 4 and 8. Serotype-specific IgG titers were measured at weeks 0, 4, 8, and 12 using indirect enzyme-linked immunosorbent assay. Antibody responses were analyzed using repeated-measures analysis of variance. Titers against poliovirus serotypes 1, 2, and 3 were negligible at baseline and remained low at week 4. Marked responses were observed in all vaccinated groups at week 8, followed by lower titers at week 12. Significant between-group differences were detected at weeks 8 and 12 for serotype 1 (p<0.001 and p=0.010), serotype 2 (both p<0.001), and serotype 3 (both p=0.010). However, no consistent dose–response pattern was observed across serotypes, time points, or sexes. All animals survived and gained body weight during follow-up. The candidate hexavalent formulations elicited marked poliovirus-specific binding-IgG responses, supporting further preclinical evaluation using validated serological and serotype-specific neutralization assays.

  • Open Access

    Phenotypic profiling of pristane‐induced mimicking human systemic lupus erythematosus in Macaca fascicularis

    by Jonny Jonny, Soetojo Wirjopranoto, Chairul A. Nidom, I Ketut Sudiana, Terawan A. Putranto, Elisa D. Pratiwi, Tiza W. Mawaddah, Astria N. Nidom, Reviany V. Nidom, Setyarina Indrasari, et al.

    Background: The development of nonhuman primate models that replicate human systemic lupus erythematosus (SLE) remains limited. This study aimed to develop a pristane‐induced SLE model in Macaca fascicularis and evaluate its capacity to mimic human‐like clinical and laboratory immunological alterations. Methods: An experimental, single‐arm investigation was performed using six female M. fascicularis (2–3 years old, 3–4 kg), which received a single intraperitoneal pristane injection (5 mL/kg body weight) to induce SLE and were monitored biweekly. Results: Throughout the 24‐week study period, all macaques developed hallmark SLE‐like changes without requiring a booster, including a pronounced increase in antinuclear antibody titers ( p = 0.002), with anti‐dsDNA positivity detected at the study endpoint. Significant decline was observed in hemoglobin, leukocyte, and lymphocyte count ( p < 0.05), reflecting hematologic perturbations consistent with human SLE. Physiologic deterioration, manifested as hyperthermia and weight loss, also emerged early ( p = 0.001). Biochemical assessment demonstrated mild hepatic and renal dysfunction marked by elevated serum glutamic pyruvic transaminase (SGPT) and urea concentrations ( p < 0.05). Uniform proteinuria further indicated renal involvement, although the absence of hematuria suggests a spectrum of renal injury that may be less severe than that observed in advanced human SLE and may require longer observation. Conclusion: Overall, the reproducibility of autoantibody elevation and multisystem involvement demonstrates the model's translational potential. This nonhuman primate model offers a significant framework for investigating SLE pathogenesis and assessing novel therapy approaches.

  • Open Access

    ANA Serum in a Non-Human Primate (Macaca fascicularis) Model of Systemic Lupus Erythematosus Induced by Pristane

    by Jonny Jonny, Pepita Zenia, Sanindita Kusumastuti, Soetojo Wirjopranoto, Chairul Anwar Nidom, I Ketut Sudiana, Elisa Diah Pratiwi, Tiza Wuri Mawaddah, Astria Novitasari Nidom, Reviany Vibrianita Nidom, et al.

    Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the production of antinuclear antibodies (ANA). While murine models are widely used for lupus research, their translational value is limited by physiological differences. Macaca fascicularis, a non-human primate, offers a closer model due to its genetic and immunological similarities to humans. Pristane (2,6,10,14-tetramethylpentadecane), a hydrocarbon oil, can induce lupus-like manifestations, including ANA production, but evidence in Macaca fascicularis remains scarce. This study assessed ANA titers following pristane induction in seven macaques, with one serving as a negative control. A single intraperitoneal dose of pristane (5 mL/kg) was administered, and ANA titers were evaluated biweekly using ELISA. ANA seropositivity (titer ≥1:80) was first detected at week 4, increasing to four macaques by week 8 and persisting at four positives in week 10. The duration of ANA positivity varied across individuals, ranging from a single week to continuous six-week responses, with one showing a biphasic pattern. The control macaque remained negative throughout. Clinical observations included alopecia, weight loss, lymphopenia, hematuria, and proteinuria in ANA-positive animals. In conclusion, pristane induced measurable autoimmunity in Macaca fascicularis, supporting its utility as a translational model for lupus research and preclinical testing of therapeutic interventions.